[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangdong Provincial Hospital of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100640297","phase-2-spatiotemporal-evolution-of-traditional-chinese-medicine-mechanisms-in-acute-ischemic-stroke-treated-with-dengzhan-xixin-and-dengzhan-shengmai-100640297",false,"NCT07591883","Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","STEM-DZ","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023\n3. Within 48 hours after the first onset\n4. National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points\n5. Voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score ≥ 2\n2. Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage\n3. patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia\n4. Patients undergoing endovascular thrombectomy\n5. Patients with severe cardiac diseases such as valvular heart disease, infective endocarditis, myocardial infarction, heart failure, severe hepatic or renal insufficiency, respiratory failure, malignant tumor, or massive gastrointestinal hemorrhage\n6. Patients who have used any preparations containing the same ingredients as the study drug (e.g., Erigeron breviscapus, ginseng, dwarf lilyturf tuber, schisandra chinensis, etc.) within the past 2 weeks\n7. Patients with a history of allergy to the study drug or preparations containing the same ingredients\n8. Pregnant or lactating women\n9. Patients judged by the investigators as unsuitable for participation in this trial.","ALL","18 Years",{"count":19,"type":20},358,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.",[27,28,29],"Ischemic Strokes","Traditional Chinese Medicine (TCM)","Prognosis",[31,28,32,33],"Ischemic Stroke","Dianzhizhengmai Capsules","Dengzhanxixin Injection","NOT_YET_RECRUITING","2026-05-11",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":20},"2026-06-01",{"date":42,"type":20},"2029-07-31",{"name":44,"class":45},"Guangdong Provincial Hospital of Traditional Chinese Medicine","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100299612","baduanjin-eight-silken-movement-with-self-efficacy-building-for-patients-with-chronic-heart-failure-besmile-hf-study-100299612","NCT03180320","Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)","Effect of an Exercise-based Cardiac Rehabilitation Program 'Baduanjin-eight-silken-movement With Self-efficacy Building' for Patients With Chronic Heart Failure in Guangzhou, China (BESMILE-HF Study)","BESMILE-HF","Inclusion Criteria:\n\n1. aged 18 years or above\n2. diagnosed with chronic heart failure\n3. clinically stable as defined as symptoms and signs that have remained generally unchanged for at least 1 month\n4. NYHA functional class II or III\n\nExclusion Criteria:\n\n1. patients who have contraindications to cardiopulmonary test\n2. patients who have contraindications to exercise training\n3. Patients who have serious acute or chronic organic disease or mental disorders\n4. history of cardiac surgery, cardiac resynchronization therapy, or intracardiac defibrillation within the previous 3 months;\n5. history of cardiac arrest within 1 year;\n6. history of peripartum cardiomyopathy, hyperthyroid heart disease, primary pulmonary hypertension;\n7. inability to perform a bicycle stress test;\n8. severe cognitive dysfunction precluding informed consent or understanding of exercise concepts;\n9. current regular Baduanjin or current participation in a conventional cardiac rehabilitation program\n10. current participation in another trial.",{"count":55,"type":20},150,[57],"NA","Chronic heart failure (CHF) is a major and growing public health problem and poses economic burden on the society. There is a need for a safe, equipment-free, low-cost, and easily implemented exercise-based cardiac rehabilitation program for CHF patients in China. Baduanjin exercise, translated as 'eight silken movements', is one of the most common forms of traditional Chinese exercise and it could have value to be integrated into a exercise-based cardiac rehabilitation program for CHF patients, together with education, evaluation and consultancy. Accordingly, the BESMILE-HF program applying the Baduanjin exercise as the central component, has been developed in Guangdong Provincial Hospital of Chinese Medicine which is one of the largest hospitals of Chinese medicine in China. This project is to evaluate the efficacy and acceptability of BESMILE-HF program in patients with CHF in China, and it will be based on a randomized controlled trial and a qualitative study.",[60,61,62],"Heart Failure NYHA Class II","Heart Failure NYHA Class III","Heart Failure",[64,65,66],"chronic heart failure","exercise-based cardiac rehabilitation","Baduanjin","RECRUITING","2025-05-14",{"date":70,"type":38},"2025-05-18",{"date":72,"type":38},"2018-10-22",{"date":74,"type":20},"2026-06-30",{"name":44,"class":45},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":101},"100545120","study-on-heart-failure-with-preserved-ejection-fraction-with-qishen-granules-100545120","NCT06377761","Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules","A Randomized, Double-blind, Placebo-controlled Study on the Treatment of Heart Failure with Preserved Ejection Fraction with Qishen Granules Based on Cardiopulmonary Exercise Test","Inclusion Criteria:\n\n1. Sign the informed consent form\n2. Age 18-85 years old\n3. Heart failure was diagnosed ≥ 3 months before enrollment, The heart function classification II-IV of New York Heart Association (NYHA)\n4. has ≥ 1 of the following: 1） Structural heart disease (left atrial enlargement and\u002For left ventricular hypertrophy) recorded by echocardiography at the time of enrollment；2）Hospitalization due to heart failure within 12 months before enrollment\n5. Retention of ejection fraction: left ventricular ejection fraction (LVEF)≥50% (Echocardiography)\n6. Increase of NTpro-BNP (patients without atrial fibrillation\\>220pg\u002FmL, patients with atrial fibrillation\\>660pg\u002FmL\n7. If diuretics are being administered orally, the dose must be stable for ≥ 2 weeks before inclusion in the study\n8. At the time of randomization, it was clinically stable without signs of decompensation of cardiac failure (judged by the investigator)\n\nExclusion Criteria:\n\n1. Patients with decompensated heart failure\n2. Glomerular filtration rate (eGFR)\\\u003C30mL\u002Fmin\u002F1.73m 2\n3. Atrial fibrillation or atrial flutter with obvious liver disease or ALT, AST 3 times higher than the upper limit of normal\n4. Symptomatic hypotension or systolic blood pressure (SBP)\\\u003C100mmHg at the time of inclusion or baseline\n5. Resting heart rate recorded by echocardiography at the time of screening\\>110bpm\n6. Currently participating in another research equipment or drug test, or less than 30 days after the completion of another research equipment or drug test or receiving other research treatment. Patients participating in purely observational trials will not be excluded\n7. At present, people who are taking traditional Chinese medicine or Chinese patent medicine with similar effect to Qishen Granules\n8. Be allergic to any component of Qishen granules (astragalus membranaceus, salvia miltiorrhiza, and black aconite)\n9. Patients who refuse to sign the informed consent form or estimate poor compliance and women who are pregnant, nursing or planning to become pregnant during the trial","85 Years",{"count":86,"type":20},80,[57],"With the cardiopulmonary exercise testing as the primary outcome, the study aims to evaluate the efficacy of Qishen Granules on cardiac function, quality of life and biomarker level of patients with heart failure with preserved ejection fraction (HFpEF), which will provide evidence for the treatment of HFpEF with traditional Chinese medicine.",[90],"Heart Failure with Preserved Ejection Fraction",[90,92,93],"Qishen Granules","Cardiopulmonary Exercise Test","2024-12-15",{"date":96,"type":38},"2024-12-18",{"date":98,"type":38},"2023-05-01",{"date":74,"type":20},{"name":44,"class":45},2,""]